Home/Pipeline/Guard-cDC1s

Guard-cDC1s

Solid Tumors

Pre-clinicalActive

Key Facts

Indication

Solid Tumors

Phase

Pre-clinical

Status

Active

Company

Guardian Bio

About Guardian Bio

Guardian Bio is a private, pre-clinical stage biotech developing a novel dendritic cell therapy platform for solid tumors. The company's approach centers on generating 'Guard-cDC1s' from patient-derived stem cells to overcome a key bottleneck in cancer immunity—the dysfunction of critical antigen-presenting cells. Founded by a team with expertise in immunology, business, and pioneering dendritic cell research, the company is positioned to address a significant unmet need in oncology, though it faces the typical high-risk, high-reward path of novel cell therapy development.

View full company profile

Therapeutic Areas

Oncology Solid Tumors

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed